← Back to Screener
Burning Rock Biotech Limited American Depositary Shares (BNR)
Price$9.21
Value ScoreB
Growth ScoreD
Momentum ScoreC
Favorite Metrics
Price vs S&P 500 (26W)-65.27%
Price vs S&P 500 (4W)-45.04%
VGM Score48.37
Market Capitalization$14.19M
All Metrics
Book Value / Share (Quarterly)$0.73
P/TBV (Annual)2.82x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)-1.42%
Cash Flow / Share (Quarterly)$-0.04
Price vs S&P 500 (YTD)-62.45%
Gross Margin (TTM)74.67%
Net Profit Margin (TTM)-10.26%
EPS (TTM)$-0.08
10-Day Avg Trading Volume0.03M
EPS Excl Extra (TTM)$-0.08
Revenue Growth (5Y)4.65%
EPS (Annual)$-0.08
ROI (Annual)-10.30%
Gross Margin (Annual)74.67%
Net Profit Margin (5Y Avg)-105.68%
Cash / Share (Quarterly)$0.65
Revenue Growth QoQ (YoY)0.23%
ROA (Last FY)-6.75%
Revenue Growth TTM (YoY)4.60%
EBITD / Share (TTM)$-0.08
ROE (5Y Avg)-56.42%
Operating Margin (TTM)-10.16%
Cash Flow / Share (Annual)$-0.05
P/B Ratio1.22x
P/B Ratio (Quarterly)2.82x
Net Income / Employee (Annual)$-12,221
EV / Revenue (TTM)0.33x
Net Interest Coverage (TTM)-10.37x
ROA (TTM)-6.68%
EPS Incl Extra (Annual)$-0.08
Current Ratio (Annual)2.99x
Quick Ratio (Quarterly)2.68x
3-Month Avg Trading Volume0.02M
52-Week Price Return213.27%
Revenue / Employee (TTM)$119,103
Tangible BV / Share (Quarterly)$0.73
P/S Ratio (Annual)1.21x
Asset Turnover (Annual)0.66x
52-Week High$41.72
Operating Margin (5Y Avg)-107.01%
EPS Excl Extra (Annual)$-0.08
CapEx CAGR (5Y)-41.94%
Tangible BV CAGR (5Y)-26.04%
26-Week Price Return-57.34%
Quick Ratio (Annual)2.68x
13-Week Price Return-59.68%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)2.99x
Enterprise Value$26.14M
Revenue / Share Growth (5Y)-39.50%
Asset Turnover (TTM)0.65x
Book Value / Share Growth (5Y)-26.45%
Revenue / Employee (Annual)$119,103
Inventory Turnover (Annual)2.29x
Pretax Margin (Annual)-9.97%
Cash / Share (Annual)$0.65
3-Month Return Std Dev113.94%
Gross Margin (5Y Avg)70.34%
Net Income / Employee (TTM)$-12,221
ROE (Last FY)-10.34%
Net Interest Coverage (Annual)-9.73x
EPS Basic Excl Extra (Annual)$-0.08
P/FCF (TTM)16.59x
Receivables Turnover (TTM)3.10x
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-0.08
Receivables Turnover (Annual)3.10x
ROI (TTM)-9.94%
P/S Ratio (TTM)1.21x
Pretax Margin (5Y Avg)-105.20%
Revenue / Share (Annual)$0.75
Tangible BV / Share (Annual)$0.73
Price vs S&P 500 (52W)188.90%
Year-to-Date Return-54.29%
5-Day Price Return5.50%
EPS Normalized (Annual)$-0.08
ROA (5Y Avg)-40.98%
Net Profit Margin (Annual)-10.26%
Month-to-Date Return-1.18%
EBITD / Share (Annual)$-0.05
Operating Margin (Annual)-10.16%
LT Debt / Equity (Annual)0.00x
ROI (5Y Avg)-56.40%
LT Debt / Equity (Quarterly)0.00x
EPS Basic Excl Extra (TTM)$-0.08
P/TBV (Quarterly)2.82x
P/B Ratio (Annual)2.82x
Inventory Turnover (TTM)2.29x
Pretax Margin (TTM)-9.97%
Book Value / Share (Annual)$0.73
Price vs S&P 500 (13W)-67.93%
Beta1.41x
Revenue / Share (TTM)$0.78
ROE (TTM)-9.97%
52-Week Low$2.88
vGradeB
gGradeD
mGradeC
vgmGradeC
Show chart for
Analyst Recommendations
Oct 2023
Nov 2023
Dec 2023
Jan 2024
4.00
4.00
4.00
4.00
Industry Peers — Health Services(28)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
BNRBurning Rock Biotech Limited American Depositary Shares | B | D | C | $9.21 |
| NTRANatera, Inc. Common Stock | F | A | C | $215.31 |
| DGXQuest Diagnostics Inc. | C | D | C | $200.29 |
| LHLabcorp Holdings Inc. | C | D | C | $265.15 |
| EXASExact Sciences Corp | F | B | B | $0.00 |
| GHGuardant Health, Inc. Common Stock | F | A | B | $125.61 |
| CAICaris Life Sciences, Inc. Common Stock | F | A | D | $16.49 |
| CELCCelcuity Inc. Common Stock | — | — | C | $88.28 |
| RDNTRadNet, Inc. Common Stock | D | C | C | $54.34 |
| VCYTVeracyte, Inc. | D | A | B | $48.73 |
| GRALGRAIL, Inc. Common Stock | D | A | C | $59.98 |
About
Burning Rock Biotech develops NGS-based cancer diagnostics platforms that help oncologists select optimal therapies for patients. The company operates through two revenue-generating channels: a central laboratory model serving smaller hospitals and an in-hospital model for larger medical centers, with the central laboratory business generating the majority of revenues. Its product portfolio includes Pan-HEME, OncoScreen-WES, brPROPHET, and OncoScreen Plus, supplemented by pharma research and development services.